Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ubiquitin specific peptidase 1 | Starlite/ChEMBL | No references |
Homo sapiens | tumor susceptibility 101 | Starlite/ChEMBL | No references |
Homo sapiens | lysine (K)-specific demethylase 4A | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | transcription factor btf3, putative | 0.007 | 0.4319 | 0.5 |
Brugia malayi | hypothetical protein | 0.0084 | 0.6089 | 0.6089 |
Trypanosoma cruzi | transcription factor btf3, putative | 0.007 | 0.4319 | 0.5 |
Giardia lamblia | PHD finger protein 15 | 0.0035 | 0 | 0.5 |
Schistosoma mansoni | tsg101-related | 0.007 | 0.4335 | 0.6157 |
Echinococcus multilocularis | Transcription factor, JmjC domain containing protein | 0.0115 | 1 | 1 |
Leishmania major | basic transcription factor 3a, putative | 0.007 | 0.4319 | 0.5 |
Echinococcus granulosus | lysine specific demethylase 5A | 0.0043 | 0.0925 | 0.0925 |
Echinococcus multilocularis | tumor susceptibility gene 101 protein | 0.0084 | 0.6089 | 0.6089 |
Plasmodium falciparum | basic transcription factor 3b, putative | 0.007 | 0.4319 | 1 |
Trypanosoma brucei | transcription factor BTF3, putative | 0.007 | 0.4319 | 0.5 |
Schistosoma mansoni | tsg101-related | 0.007 | 0.4335 | 0.6157 |
Trichomonas vaginalis | conserved hypothetical protein | 0.007 | 0.4319 | 1 |
Echinococcus granulosus | jumonji domain containing protein | 0.0049 | 0.1721 | 0.1721 |
Loa Loa (eye worm) | jmjC domain-containing protein | 0.0073 | 0.468 | 0.7686 |
Brugia malayi | jmjC domain containing protein | 0.0043 | 0.0925 | 0.0925 |
Brugia malayi | beta-NAC-like protein | 0.007 | 0.4319 | 0.4319 |
Echinococcus granulosus | tumor susceptibility gene 101 protein | 0.0084 | 0.6089 | 0.6089 |
Echinococcus granulosus | transcription factor btf3 | 0.007 | 0.4319 | 0.4319 |
Schistosoma mansoni | tsg101-related | 0.0057 | 0.2736 | 0.3885 |
Echinococcus multilocularis | jumonji domain containing protein | 0.0049 | 0.1721 | 0.1721 |
Loa Loa (eye worm) | jmjC domain-containing protein | 0.0043 | 0.0925 | 0.1519 |
Trichomonas vaginalis | conserved hypothetical protein | 0.007 | 0.4319 | 1 |
Entamoeba histolytica | hypothetical protein | 0.007 | 0.4319 | 1 |
Loa Loa (eye worm) | ICD-1 protein | 0.007 | 0.4319 | 0.7093 |
Echinococcus granulosus | Transcription factor JmjC domain containing protein | 0.0115 | 1 | 1 |
Schistosoma mansoni | jumonji domain containing protein | 0.0092 | 0.7041 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0084 | 0.6089 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.314 | 0.5157 |
Schistosoma mansoni | transcription factor btf3 | 0.007 | 0.4319 | 0.6133 |
Echinococcus multilocularis | lysine specific demethylase 5A | 0.0043 | 0.0925 | 0.0925 |
Echinococcus multilocularis | transcription factor btf3 | 0.007 | 0.4319 | 0.4319 |
Schistosoma mansoni | jumonji/arid domain-containing protein | 0.0043 | 0.0925 | 0.1313 |
Schistosoma mansoni | jumonji/arid domain-containing protein | 0.0043 | 0.0925 | 0.1313 |
Toxoplasma gondii | NAC domain-containing protein | 0.007 | 0.4319 | 1 |
Plasmodium vivax | basic transcription factor 3b, putative | 0.007 | 0.4319 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.007 | 0.4319 | 1 |
Entamoeba histolytica | transcription factor BTF3, putative | 0.007 | 0.4319 | 1 |
Onchocerca volvulus | Alhambra homolog | 0.0035 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (binding) | > 300 um | PUBCHEM_BIOASSAY: Fluorescent Polarization Homogeneous Dose Response HTS to Identify Inhibitors of Mex-5 Binding to TCR-2. (Class of assay: confirmatory) [Related pubchem assays: 1833 (Project Summary), 1832 (Primary HTS)] | ChEMBL. | No reference |
EC50 (binding) | > 300 um | PUBCHEM_BIOASSAY: Fluorescent Polarization Homogeneous Dose Response HTS to Identify Inhibitors of POS-1 Binding to mex-3-RNA. (Class of assay: confirmatory) [Related pubchem assays: 1833 (Project Summary), 1832 (Primary HTS)] | ChEMBL. | No reference |
Potency (functional) | 0.0033 uM | PubChem BioAssay. qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101: Hit Validation in TR assay. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 15.8489 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 15.8489 uM | PubChem BioAssay. Inhibitors of USP1/UAF1: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 21.3313 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Vif-A3F Interactions: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485342, AID485388] | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PubChem BioAssay. qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PubChem BioAssay. qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.